CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer

CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer

Abstract Background Androgen deprivation therapy (ADT) is still the first-line treatment of prostate cancer (PCa). However, after a certain period of therapy, primary PCa inevitably progresses into castration-resistant PCa (CRPC). Enzalutamide (Enz) is an androgen receptor (AR) signal inhibitor whic...

Full description

Bibliographic Details
Main Authors: Xi Chen, Yechen Wu, Xinan Wang, Chengdang Xu, Licheng Wang, Jingang Jian, Denglong Wu, Gang Wu
Format: Article
Language:English
Published: BMC 2022-07-01
Series:European Journal of Medical Research
Subjects:
Differentially expressed genes
Castration-resistant prostate cancer
Enzalutamide
Hub gene
Cyclin-dependent kinase 6
Therapeutic target
Online Access:https://doi.org/10.1186/s40001-022-00730-y

Internet

https://doi.org/10.1186/s40001-022-00730-y

Similar Items